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Abstract
Introduction: To evaluate the association between abdominal and gynoid fat, glucose and lipid metabolism markers, and serum androgens 
in women with polycystic ovary syndrome (PCOS).
Material and methods: Anthropometric measurements were performed in 40 women with PCOS aged 19–49 years with body mass index 
(BMI) 18.7–53.8 kg/m2. Fasting serum glucose, lipids, insulin, leptin, LH, FSH, oestradiol, androgens, SHGB and TSH were estimated. Body 
composition was measured by DEXA scan.
Results: Four women (10%) were overweight, and 23 (57.5%) were obese. All subjects were hyperandrogenic (in 33 serum androgen 
levels were increased), and 16 of them were insulin resistant. All of the obese subjects had the abdominal type of obesity. Body weight, BMI, 
fat mass, fat mass of the trunk, abdominal and gynoidal fat mass correlated with serum triglyceride, glucose and insulin levels, and with 
HOMA index and blood pressure. Free androgen index (FAI) correlated with body weight (r = 0.43, p < 0.01), and BMI (r = 0.46, p < 0.05).
Conclusions: Using the DEXA method, we demonstrated abdominal type of obesity in all our obese subjects. There were positive significant 
correlations between fatness, lipids and glucose metabolism indices and blood pressure. Direct positive correlations between free androgen 
index, body weight and BMI were found.  (Endokrynol Pol 2013; 64 (2): 94–100)
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Streszczenie
Wstęp. Ocena zależności między masą tłuszczu adipoidalnego i gynoidalnego a wskaźnikami metabolizmu węglowodanów i lipidów 
oraz androgenami u kobiet z zespołem policystycznych jajników (PCOS). 
Materiał i metody: U 40 kobiet z PCOS w wieku 19–49 lat, z BMI 18,7–53,8 kg/m2 dokonano pomiarów antropometrycznych oraz określono 
na czczo stężenie glukozy, lipidów, insuliny, leptyny, LH, FSH, estradiolu, androgenów, SHBG i TSH. Skład ciała oceniono metodą DEXA. 
Wyniki: Cztery kobiety (10%) miały nadwagę, dwadzieścia trzy (57,5%) były otyłe. U wszystkich badanych stwierdzono hiperandrogenizm 
(u 33 stężenie androgenów w surowicy było podwyższone), a u 16 oporność insulinową. Wszystkie osoby otyłe miały otyłość brzuszną. 
Wykazano korelację między masą ciała, BMI, masą tłuszczu całkowitego i tułowia, a także tłuszczu adipoidalnego i gynoidalnego a stęże-
niem triglicerydów, glukozy, insuliny, HOMA i wartościami ciśnienia tętniczego. Wskaźnik wolnych androgenów (FAI) wykazywał korelację 
z masą ciała (r = 0,43, p < 0,01) i BMI (r = 0,46, p < 0,05). 
Wnioski: Za pomocą metody DEXA wykazano brzuszny typ otyłości u wszystkich badanych otyłych kobiet z PCOS. Stwierdzono dodatnią 
korelację między wykładnikami otyłości a badanymi wskaźnikami metabolizmu lipidów i węglowodanów oraz wartościami ciśnienia tętniczego 
krwi. Wykazano bezpośrednią korelację między wskaźnikiem wolnych androgenów a masą ciała i BMI.  (Endokrynol Pol 2013; 64 (2): 94–100)
Słowa kluczowe: zespół policystycznych jajników, skład ciała, otyłość, hiperandrogenizm, insulinooporność
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Introduction
Polycystic ovary syndrome (PCOS) is considered to 
be the most frequent endocrine disorder in women 
of reproductive age and is present in 5–10% of them 
[1]. The criteria for diagnosing this syndrome were 
determined by the international consensus confer-
ence in Rotterdam in 2003 [2]. The pathogenesis of 
PCOS is still far from clear, and it most likely results 
from a complex of genetic and environmental factors. 
Women with this syndrome present with marked 
clinical heterogeneity, although hyperpulsatile gon-
adotrophin secretion, disturbed ovarian and adrenal 
steroidogenesis, menstrual irregularity, reduced 
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levels of SHBG, and insulin resistance are common 
features [3–5]. The arrest of antral follicle growth that 
is observed in PCOS is associated with an abnormal 
endocrine environment throughout the menstrual 
circle: hypersecretion of luteinising hormone (LH), 
and perhaps androgens, and suppression of follicle-
stimulating hormone (FSH). Moreover, the intrinsic 
abnormalities of folliculogenesis in PCOS that affects 
the very earliest, gonadotrophin independent, stages 
of follicle development (abnormal granulosa cell 
proliferation and disparate growth of oocyte and 
surrounding granulosa cells) perhaps contribute to 
inhibition of maturation of follicles in the cohort. 
Also abnormal signalling of local regulators: anti-
Müllerian hormone, insulin-like growth factors and 
sex steroids may play a part in disordered follicu-
logenesis in PCOS. Since eggs are rarely or never 
released from their follicles — multiple ovarian cysts 
develop over time. 
Approximately half of the patients with PCOS are 
overweight or obese [6]. Abdominal obesity that seems 
to predominate in these cases is a major underlying 
factor in insulin resistance. However, decreased insulin 
sensitivity with subsequent hyperinsulinaemia was 
found also in lean women with PCOS [7]. Excessive 
adipose tissue, especially abdominal fat, secretes sev-
eral metabolic factors, with proinflammatory cytokines 
among them. In recent studies, elevated inflamma-
tory markers, perturbations in fibrinolytic pathways 
and endothelial dysfunction — a sign of subclinical 
cardiovascular damage, have been shown in women 
with PCOS [8-9]. Foltyn et al. demonstrated elevated 
levels of E-selectin, endothelin-1 and von Willebrand 
Factor antigen — markers of endothelial dysfunction in 
women, with this syndrome [10]. Also, androgen excess 
and fertility disorders contribute to vascular damage 
in PCOS [11].
A number of different methods of investigating 
body composition have been devised. Noninvasive, 
anthropometric measures are widely used because of 
their simplicity and convenience. Techniques of directly 
measuring adiposity including computed tomography, 
total body water or total body potassium estimations 
have important limitations: exposure to ionising radia-
tions, relatively high cost or methodological complexity. 
In our study, we used dual-energy X-ray absorptiometry 
(DEXA).This allows accurate and simple measurement, 
both of total and regional fat, with marginal exposure 
to radiation. 
The aim of our study was to evaluate the asso-
ciation between abdominal and gynoid fat, glucose 
and lipid metabolism markers, blood pressure and 
serum androgen levels in women with polycystic 
ovary syndrome.
Material and methods
We evaluated 40 women with PCOS aged 19-49 years, 
mean 28.6 ± 7.6 (x ± SD) with BMI 18.7 – 53.8 kg/m2, 
mean 32.27 ± 9.3 The diagnosis of PCOS was based on 
the Rotterdam consensus criteria: the presence of at least 
two of the following features: 1) oligomenorrhoea or 
amenorrhoea; 2) clinical and/or biochemical evidence 
of hyperandrogenaemia; and 3) polycystic ovaries in 
ultrasound imaging. Oligomenorrhoea was defined as 
menstrual periods that occur at intervals of greater than 
35 days, with only four to nine periods in a year, and 
amenorrhoea as the complete absence of menstruation.
Clinical hyperandrogenaemia was defined as the 
presence of hirsutism or acne. Biochemical hyperan-
drogenaemia was defined as serum testosterone levels 
greater than 0.9 ng/mL, dehydroepiandrosterone-sul-
phate levels greater than 2,000–4,100 ng/mL depending 
on age, or free androgen index (FAI) > 5.
Ovaries in USG were defined as polycystic when 
they included either ten or more follicles measuring 
2–9 mm in diameter or their volume was greater than 
10 cm3.
The exclusion criteria included hypothyroidism, 
hyperprolactinaemia (defined as serum prolactin levels 
greater than 25 ng/mL), Cushing’s syndrome, nonclas-
sical congenital adrenal hyperplasia (defined as serum 
17-hydroxyprogesterone levels greater than 1.2 and 
5.2 ng/mL in the follicular and luteal phase, respec-
tively) and current or previous (within the last three 
months) use of oral contraceptives and other hormonal, 
antidiabetic and antiobesity drugs.
A screening session included full physical exami-
nation, laboratory tests and imaging. Subjects were 
studied after an overnight fast. They underwent as-
sessment of body height and weight, and then body 
mass index (BMI) was calculated. Blood was collected 
at about 8.00am for glucose, lipids (total cholesterol, 
low-density lipoprotein cholesterol, high-density 
lipoprotein cholesterol and triglycerides), insulin, 
leptin, LH, FSH, oestradiol, testosterone, dehydroe-
piandrosterone-sulphate, 17-hydroxyprogesterone, 
sex hormone-binding globulin (SHBG), prolactin, free 
thyroxine, and thyroid-stimulated hormone (TSH) 
through an iv catheter placed in the forearm. FAI was 
calculated as testosterone (nmol/L)/SHBG (nmol/L) 
levels. To estimate insulin resistance, the HOMA index 
was calculated by the formula: fasting plasma insulin 
(microinternational units per millilitre) x fasting plasma 
glucose (millimoles per litre)/22.4. Subjects were consid-
ered as insulin resistant when HOMA index was > 2.5. 
Hypercholesterolaemia was defined as total cholesterol 
level above 5.2 mmol/L and hypertriglycerydaemia 
when triglycerides levels were higher than 1.81 mmol/L. 
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During the same stay in hospital, but usually on an-
other day, all of the subjects underwent transvaginal 
ultrasonography (TV-USG) and USG of abdomen (to 
exclude adrenal pathology). At the end of the investiga-
tion, body composition by DEXA was determined. The 
same two operators performed all TV-USG and DEXA 
measurements, respectively. 
The local ethics committee approved this study, 
and informed consent was obtained from all the par-
ticipants.
Assays
 Glucose was measured with glucose hexokinase 
reagent set with sensitivity 2.16 mg/dL. An enzymatic 
colorimetric method was used to measure total choles-
terol in the presence of cholesterol oxidase and esterase. 
The sensitivity was 0.116 mg/dL. HDL-cholesterol was 
measured with the enzymatic colorimetric method; sen-
sitivity was 3 mg/dL. Triglycerides were also measured 
with the enzymatic colorimetric method with sensitivity 
0.85 mg/dL. All mentioned biochemical measurements 
were performed using a Roche Cobas Integra 400 
chemistry analyser (Roche Diagnostics). Insulin was 
measured by the immunoradiometric method (Insulin 
IRMA — Immunotech SA, France); sensitivity was 
2.0 mIU/mL. Leptin was measured by RIA (Linco Res. 
Inc, USA), using rabbit antibodies against human leptin. 
The sensitivity for this assay was 0.5 ng/mL. 
LH, FSH and TSH were measured by the immu-
nochemiluminescence method with IMMULITE 2000 
(Siemens Healthcare Diagnostics, Inc). Oestradiol 
was measured with the same IMMULITE 2000 ana-
lyser; sensitivity was 15 pg/mL. Total testosterone was 
measured by the RIA-CT method (Immunotech SA, 
France); sensitivity of this method was 0.025 ng/mL. 
Dehydroepiandrosterone-sulphate was measured 
by the RIA-CT method (Spectria, Orion Diagnostica, 
Finland); sensitivity of this method was 10 ng/mL. 
17-hydroxyprogesterone was measured by 17OH-RIA-
CT Kit (DIAsource ImmunoAssays SA, Belgium); detec-
tion limit: 0.02 ng/mL. SHBG was measured by IRMA 
method (Orion Diagnostics Oy, Finland); detection limit 
1.3 nmol/L. Prolactin was measured by IMMULITE 2000 
(Siemens Healthcare Diagnostics, Inc); sensitivity of this 
method was 0.01 µg/mL.
Body mass index was calculated as body weight 
[kg]/height [m2]. Subjects with BMI between 25 and 
30 kg/m2 were considered to be overweight, whereas 
subjects with BMI between 30 and 40 kg/m2 were con-
sidered to be obese, and with BMI above 40 kg/m2 to 
be morbidly obese.
To perform measurements of fat mass, we used a 
region of interest (ROI) programme. In this method, 
abdominal fat is estimated in the region between the 
upper part of the pelvis with the upper margin 96 mm 
superior to the lower part of this region. The lateral 
part of this region is defined by the lateral part of the 
thorax. The upper part of the gynoid fat region is de-
fined by the superior part of the trochanter major, with 
the lower margin 96 mm inferior to the upper part of 
the trochanter major. The lateral part of this region is 
defined by the subcutaneous tissue on the hip, which 
can be visualised using the Image Values option (Fig. 1). 
We used Lunar Prodigy (GE Lunar, Madison, WI, USA) 
equipment, which was calibrated each day with a stand-
ardised phantom and serviced regularly. The coefficient 
of variation for measurements of body composition 
with this method is about 2%.
Statistical analysis
 All data is presented as the mean ± SD. The normal-
ity of the distribution of variables was verified with 
Kolmogorov-Smirnov and Lilieforse tests. To examine 
bivariate relationships between data, Pearson correla-
tion or Spearman rank analyses were used. Compari-
Figure 1. Example of the regions of interest (ROI) delimiting 
abdominal (1) and gynoid (2) fat in one of our studied obese women 
with polycystic ovary syndrome
Rycina 1. Przykład regionów (ROI) wyznaczających obszary 
tłuszczu brzusznego (1) i gynoidalnego (2) u badanych kobiet z 
zespołem policystycznych jajników
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sons between groups with normal distribution of the 
data were performed by unpaired Student’s t-test, in 
other cases comparisons were performed by Kolmog-
orov-Smirnov test for two samples. For all analysis, a 
two-tailed p ≤ 0.05 was considered to indicate statistic 
significance.
Results
Forty women participated in the study. Their mean age 
was 28.62 ± 7.6 years. Table I shows anthropometric 
data, body composition, blood pressure and biochemi-
cal estimations of the studied subjects. This cohort rep-
resented a relatively broad range of age. Four patients 
(10%) were overweight, 23 were obese (57.5%), and nine 
were considered to be morbidly obese. All of the obese 
subjects had increased abdominal fat. Three women were 
hypertensive, with increased diastolic blood pressure. 
They had not taken any hypotensive drugs before their 
recent diagnosis. In 14 women, hypercholesterolaemia 
and in 11 hypertriglyceridaemia were found.
Table II sets out the hormonal results of the studied 
women. Thirty-three subjects were hyperandrogenic 
and all except one were euthyrotic (one woman met 
the hormonal criteria of subclinical hyperthyroidism). 
Twelve had elevated fasting serum insulin levels, and 
16 were considered as insulin resistant according to 
HOMA index.
Correlation between blood lipids, glucose metabo-
lism markers, blood pressure and estimates of fatness 
in study subjects are presented in Table III. All indices 
of adiposity significantly positively correlated with all 
except total cholesterol metabolic parameters. In Figure 
2, a significant positive correlation between fat mass of 
the trunk (kg) and HOMA index is shown. 
Table IV presents correlation between estimates 
of adiposity and serum hormones. We found a sig-
nificant positive correlation between fat estimates 
and leptin levels. FAI positively correlated with body 
weight and BMI. No other correlation between fat 
mass indices and sex hormones was found. Figure 
3 presents a significant positive correlation between 
FAI and body mass index. 
Discussion
In our study, we separated and measured abdominal 
and gynoid fat in patients with PCOS using the DEXA 
method. It turned out that in all obese subjects, abdomi-
nal fat was increased. Our data revealed a significant 
correlation between fatness and serum fasting glucose 
and insulin levels, as well as HOMA index of insulin 
resistance. We also observed a positive correlation 
between estimates of obesity and serum triglycerides 
and between obesity and blood pressure. In the end, 
we demonstrated direct positive correlations between 
free androgen index, body weight and BMI. 
Table I. Anthropometric characteristics, body composition, 
blood pressure and biochemical results in women with 
polycystic ovary syndrome
Tabela I. Wskaźniki antropometryczne, skład ciała, ciśnienie 
tętnicze i wyniki badań biochemicznych u kobiet z zespołem 
policystycznych jajników
No N Mean ± SD Range
1 Age (years) 40 28.62 ± 7.6 19.0–49.0
2 Height [m] 40 1.6 ± 0.06 1.51–1.85
3 Weight [kg] 40 88.3 ± 27.1 48.0–163.0
4 BMI [kg/m2] 40 32.26 ± 96.3 18.7–53.8
5 Total FM [kg] 36 41.4 ± 18.9 9.6–82.4
6 FMt [kg] 36 20.8 ± 9.1 4.5–36.9
7 Abdominal FM [kg] 36 3.24 ± 1.2 1.37–6.40
8 Gynoid FM [kg] 36 4.62 ± 2.3 0.34–8.3
9 Glucose [mmol/L] 40 5.02 ± 0.8 4.0–4.45
10 Total cholesterol [mmol/L] 40 6.4 ± 8.9 3.4–61.4
11 LDL cholesterol [mmol/L] 40 2.9 ± 0.87 1.42–5.51
12 HDL cholesterol [mmol/L] 40 1.42 ± 0.4 0.77–2.45
13 Triglycerides [mmol/L] 40 1.42 ± 0.86 0.44–3,8
14 Systolic BP [mm Hg] 40 123.4 ± 12 100–150
15 Diastolic BP [mm Hg] 40 77.7 ± 11.8 60–100
BMI — body mass index; FM — fat mass; FMt — fat mass of the trunk;  
BP — blood pressure; LDL — low density lipoprotein cholesterol; HDL — high 
density lipoprotein cholesterol
Table II. Hormonal results of studied women with polycystic 
ovary syndrome
Tabela II. Wyniki badań hormonalnych u kobiet z zespołem 
policystycznych jajników
No Hormone N Mean ± SD Range
1 Insulin [µIU/mL] 39 11.5 ± 9.6 1.0–33.0
2 HOMA 39 2.68 ± 2.4 0.19–9.86
3 Leptin [µg/mL] 36 34.4 ± 26.0 2.5–86.0
4 Testosterone [ng/mL] 40 0.82 ± 0.44 0.2–2.1
5 DHEA-S [ng/mL] 40 2862.7 ± 1286 518–6740
6 SHBG [nmol/L] 38 38.3 ± 23.6 9.8–115.0
7 LH/FSH 39 1.81 ± 1.8 0.97–11.1
8 Oestradiol [pg/mL] 39 58.2 ± 37.2 15–238
9 Prolactin [µg/mL] 39 15.3 ± 8.5 4.0–41.0
10 TSH [µIU/mL] 40 1.29 ± 0.7 0.012–3.31
HOMA — homeostatic model assessment; DHEA-S — dehydroepiandrosterone-
sulphate; SHBG — sex hormone-binding globulin; LH — luteinising hormone;  
FSH — follicle stimulating hormone; TSH — thyroid stimulating hormone
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Figure 2. Significant positive correlation between fat mass in 
trunk (kg) and HOMA index in studied women with polycystic 
ovary syndrome (r = 0.68; p < 0.001)
Rycina 2. Znamienna dodatnia korelacja między masą tłuszczu 
tułowia (kg) i wskaźnikiem HOMA u badanych kobiet z zespołem 
policystycznych jajników (r = 0,68; p < 0,001)
Figure 3. Significant positive correlation between FAI and body 
mass index in women with polycystic ovary syndrome (r = 0.46; 
p < 0.05) 
Rycina 3. Znamienna dodatnia korelacja między FAI 
a wskaźnikiem masy ciała u kobiet z zespołem policystycznych 
jajników (r = 0,46; p < 0,05)
Table III. Correlation between serum lipids, systolic and diastolic blood pressure, serum glucose and insulin levels and different 
estimates of fatness in our studied women with polycystic ovary syndrome. In the table, Pearson’s correlation coefficients 
(rxy) are shown
Tabela III. Korelacja między lipidami krwi, skurczowym i rozkurczowym ciśnieniem tętniczym oraz wskaźnikami otyłości 
u badanych kobiet z zespołem policystycznych jajników. W tabeli przedstawiono wskaźniki korelacji Pearsona (x, y)
Body weight BMI Total fat FMt Abdominal fat Gynoid fat
Total cholesterol 0.20 0.21 0.20 0.26 0.16 0.03
Triglycerides 0.62c 0.66c 0.59c 0.65c 0.40a 0.56c
Glucose 0.45b 0.48b 0.51b 0.40a 0.48b 0.40a
Insulin 0.69c 0.69c 0.65c 0.69c 0.35a 0.68c
HOMA 0.68c 0.68c 0.64c 0.68c 0.37a 0.65c
SBP 0.40a 0.40a 0.47b 0.48b 0.41a 0.52b
DBP 0.44b 0.43b 0.56c 0.57c 0.36a 0.65c
BMI — body mass index; FMt — fat mass of the trunk; HOMA — homeostatic model assessment; SBP — systolic blood pressure; DBP — diastolic blood pressure;  
ap < 0.05; bp < 0.01; cp < 0.001
Table IV. Correlation between serum hormones and different estimates of fatness in studied women with polycystic ovary 
syndrome. Table shows correlation coefficients (rxy)
Tabela IV. Korelacja między stężeniem hormonów w surowicy i wskaźnikami otyłości u badanych kobiet z zespołem 
policystycznych jajników. W tabeli przedstawiono wskaźniki korelacji (x, y)
Body weight BMI FM FMt Abdominal fat Gynoid fat
Leptin 0.88c 0.87c 0.89c 0.80c 0.65b 0.89c
Testosterone 0.21 0.27 0.23 0.12 –0.06 0,28
DHEA-S –0.18 –0.18 –0.12 0.02 –0.16 –0.12
FAI 0.43b 0.46a 0.33 0.39 0.13 0.39
LH/FSH –0.30 –0.25 –0.21 –0.23 –0.35a –0.21
Oestradiol 0.13 0.19 0.11 –0.22 –0.18 0.27
BMI — body mass index; FMt — fat mass of the trunk; DHEA-S — dehydroepiandrosterone sulphate; LH — luteinising hormone; FSH — follicle stimulating hormone;  
TSH — thyroid stimulating hormone; ap < 0.05; bp < 0.01; cp < 0.001
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Diagnosing PCOS according to the Rotterdam cri-
teria, we measured serum androgen levels. However, 
it has been demonstrated that also measuring salivary 
androgens may also be useful in making a diagnosis 
of this syndrome [12]. Moreover, Lewandowski et al. 
proved recently that gonadotrophin releasing hormone 
(GnRH) stimulated increase in LH/FSH ratio may be 
potentially useful as an additional tool in identifying 
patients with PCOS [13]. 
It has been previously demonstrated that ap-
proximately 40–60% of the women with PCOS are 
overweight or obese. In our study, this proportion was 
higher (67.5%). This may be the result of pre-recruit-
ment to the study of the group of women with obesity 
and PCOS from our out-patients clinic.
Some authors consider that overweight women 
with PCOS have the central type of obesity. However, 
estimations of body composition have given contrasting 
results [14–16]. In our study, we used the dual energy 
X-ray absorptiometry method to accurately estimate 
abdominal and gynoid fat. Compared to anthropologi-
cal measurements, DEXA is able to assess both total and 
regional fat mass in conditions of minimal exposure to 
radiation. We applied the technique used by Rissanen 
et al. [17] and Carmina et al. [18], who determined two 
regions of interest (ROI) including abdominal and 
gynoid fat respectively to obtain appropriate measure-
ments. We found increase in abdominal fat in all of 
our overweight and obese patients. Moreover, highly 
significant correlations between all indices of obesity, 
triglycerides, glucose, insulin and blood pressure were 
observed in our subjects. This is an important observa-
tion because metabolic implications of abdominal fat 
excess are very well known. For example, it was recently 
demonstrated, that the ‘hypertriglyceridaemic waist’ 
phenotype (hypertriglyceridaemia and increased waist 
circumference) and metabolic syndrome in patients with 
type 2 diabetes, significantly increases cardiovascular risk 
[19]. On the other hand, only three of our patients were 
slightly hypertensive, 14 had hypercholesterolaemia and/ 
/or hypertriglycerydaemia, and 16 of them were insulin 
resistant, according to HOMA index. It could be argued 
that the young age of our subjects explains at least in part 
this relatively positive data. The question as to whether 
the presence of risk factors in patients with PCOS con-
tributes to an early increase of cardiovascular events is 
still open, since follow-up studies have brought divergent 
results. In one long-term follow up, no increase in the 
risk of cardiovascular-related deaths during 30 years 
was observed, whereas in another trial, an excess of non-
fatal cerebrovascular events in women with PCOS was 
demonstrated [20, 21]. Also data regarding the incidence 
of hypertension in women with PCOS is controversial. 
In one study, the authors showed that young women 
with PCOS generally do not manifest increased blood 
pressure [22]. However, another long-term follow up 
indicates that in such patients hypertension may develop 
later in life [23].
Our results suggest that increase in fat mass, particu-
larly in the region of the abdomen, is related to and pos-
sibly responsible for insulin resistance and subsequent 
hyperinsulinaemia. One may speculate that not only 
abdominal obesity contributes to a decrease in insulin 
sensitivity in women with PCOS. It has been demon-
strated in one of the recent studies that patients with 
this syndrome had higher insulin levels and reduced 
insulin sensitivity compared to controls without PCOS, 
regardless of the degree of fatness [24]. 
We found a significant correlation between free 
androgen index (FAI) and body weight and BMI. On 
the other hand, we couldn’t demonstrate any direct cor-
relation between serum androgens (total testosterone, 
androstendione (data unpublished) and dehydroe-
piandrosterone-sulphate) and obesity. It is difficult to 
explain this discrepancy, although the role of sex hor-
mone binding proteins probably should be taken into 
account. We found relatively low SHBG levels. In this, 
our data confirms previous results that SHBG suppressed 
secondary to hyperandrogenaemia is an early finding in 
obese women with PCOS [25]. Holte et al. [26] similarly 
demonstrated a positive correlation between obesity and 
free androgen index. However, they also observed a cor-
relation between obesity and testosterone and DHEA-S 
in premenopausal women with PCOS [27]. Carmina et 
al. [18] did not find any correlation between fat param-
eters and serum testosterone levels in PCOS patients. 
The apparent divergence between our findings and data 
from other authors may be explained at least in part by 
differences in age, obesity advance and androgens levels 
in the studied groups. However, our data corroborates 
the relationship between the degree of obesity and an-
drogens levels. Moreover, there is growing evidence that 
androgen excess may be causally involved in abdominal 
fat accumulation in women [28, 29]. Hence, pharmaco-
logical or surgical amelioration of hyperandrogenaemia 
might improve the abdominal adiposity characteristic of 
PCOS and associated metabolic disorders [30, 31]. But 
our study was not designed to address this interesting 
problem.
There are some limitations to our study. Firstly, it suf-
fers from the lack of an adequate control group of healthy 
women. Secondly, it includes a relatively small number 
of studied patients. Thirdly, it was not possible to dif-
ferentiate visceral from subcutaneous fat analysing ROI 
with the DEXA method. In order to do that, computed 
tomography (CT) should be used, but the limitation of 
CT is a great exposure to ionising radiation. On the 
other hand, it has been proved that also subcutaneous 
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abdominal fat, especially its profound component, is 
metabolically active and contributes to insulin resistance 
and its subsequent metabolic and clinical consequences 
[32], so it seems that DEXA can be considered as a reliable 
method to identify and appreciate the risk associated 
with abdominal obesity. 
Conclusions
We demonstrated using the DEXA method that 
overweight and obese women with PCOS have the 
abdominal type of obesity. We found high positive cor-
relations between fatness and serum fasting glucose and 
insulin levels as well as with HOMA index. Estimates 
of obesity positively correlated with triglycerides and 
blood pressure. We also demonstrated direct positive 
correlations between free androgen index and body 
weight and BMI. 
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